

**ALL ORDERS MUST BE SIGNED, DATED AND TIMED BY PHYSICIAN**

**Allergies/Reactions:**

- Puyallup Infusion Center - Fax: 253-697-5066
- Gig Harbor Infusion Services - Fax: 253-530-8069
- Allenmore Ambulatory Infusion Services - Fax: 253-864-4052
- DHEC Infusion Center - Fax: 509-755-5845
- Auburn Infusion Services - Fax: 253-876-8282
- North Spokane Infusion Center - Fax: 509-232-2531

**ORDERS WITH CHECK BOXES**

When an order is optional (those with check boxes), physicians are responsible for indicating a check mark in the box next to the order. Orders left unchecked will not be initiated.

**Rituximab (Rituxan) or other biosimilar**

Patient Name: \_\_\_\_\_ Requested Date of Service: \_\_\_\_/\_\_\_\_/\_\_\_\_  
Date of Birth: \_\_\_\_/\_\_\_\_/\_\_\_\_ Patient Phone Number: (\_\_\_\_) \_\_\_\_\_ - \_\_\_\_\_  May leave message

- Diagnosis:**
- Rheumatoid Arthritis
  - Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)
  - Other \_\_\_\_\_
- \_\_\_\_\_
  - \_\_\_\_\_
  - \_\_\_\_\_
  - \_\_\_\_\_

**Required:** H&P with documentation to support above diagnosis including ICD-10 code and supporting labs (patient height and weight are required for BSA dosing)

*\*\*If required documentation not received with order, scheduling of treatment will be delayed until complete information is available\*\**

**Baseline labs required:**

- CBC/CMP
- Hepatitis B screening prior to initiation of rituximab therapy. Patients that test positive for HBV surface antigen must be evaluated/treated for Hepatitis B before receiving rituximab

**Maintenance labs required:**

- CBC every 3 months - Hold infusion and notify provider for ANC <1000 and/or platelets <100k

**IV Access:** Access and/or maintain IV site in accordance with MHS IV Therapy P&P: Peripheral IV Device Site Selection, Insertion, Maintenance, and Discontinuation; and Maintenance of Central Venous Catheters-Flushing, Dressing Changes and Removal.

Patient weight \_\_\_\_\_ height \_\_\_\_\_ BSA \_\_\_\_\_ (required for BSA dosing)

**Treatment Regimen (pharmacist to add MHS or insurance preferred product):**

- Rituximab for RA: Rituximab 1000 mg or \_\_\_\_\_ mg IV on days 1 & 15 every 6 months x 1 year
  - Pre-meds given 30 minutes prior to rituximab:
    - Methylprednisolone 125 mg IV x 1 dose
    - Acetaminophen 650 mg po x 1 dose
    - Diphenhydramine 25 mg po x 1 dose or loratadine 10 mg po x 1 dose if intolerant to diphenhydramine
- Rituximab for GPA and MPA: 375 mg/m<sup>2</sup> or \_\_\_\_\_ mg IV every week x 4 doses
  - Pre-meds given 30 minutes prior to rituximab:
    - Acetaminophen 650 mg po x 1 dose
    - Diphenhydramine 25 mg po x 1 dose or loratadine 10 mg po x 1 dose if intolerant to diphenhydramine

**Rituximab infusion will be titrated per pharmacy protocol**

**Vital Signs:** Check vital signs prior to and at completion of infusion.  
Contact provider if systolic BP >180; diastolic BP >100; systolic BP <90; HR >110; temp >38C (100.4F)

**If hypersensitivity develops (fever, chills, hypotension, rigors, itching, rash, etc.):**

- Consult MultiCare hypersensitivity guideline for treatment management
- Notify provider of reaction, assessment and need for further orders

**Code Status:** Please note, patients will be considered FULL Code unless marked otherwise. If the patient has a POLST, advance directive or living will, please include a copy with the orders.

**Was consent obtained:**  Yes  No (if yes, please send DOCUMENTATION of consent with order)

Provider Signature \_\_\_\_\_ Print Name \_\_\_\_\_ Date \_\_\_\_\_ Time \_\_\_\_\_

Another brand of drug, identical in form and content, may be dispensed unless checked

Orders expire in 12 months\*\*

**Patient Identification - Always Attach Patient Label**

Name: \_\_\_\_\_  
MRN #: \_\_\_\_\_  
CSN #: \_\_\_\_\_  
Age / Sex and Gender: \_\_\_\_\_

Pre-printed Order  
**RITUXIMAB (Rituxan) INFUSION**

**MultiCare** 



78-0025-7MR (Rev. 7/24)